ERBB2 and breast cancer: The study hypothesized that the addition of a CDKi to anti-HER2 and endocrine therapy after induction therapy would delay the onset of therapeutic resistance, prolong survival, and improve endocrine resistance in HR+/HER2 breast cancer [40].